MedTrace Logo

Furocyst - Poly Cystic Ovary Syndrome Study

NCT02703064 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2017-09-15

No results posted yet for this study

Summary

Poly cystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting approximately 5%-10% of all females worldwide . PCOS is a hormonal disorder that involves multiple organ systems within the body. Its cardinal features are Hyperandrogenism and polycystic ovary (PCO) morphology. Women with PCOS may complains about irregular menstrual periods or heavy menstrual bleeding, infertility, excessive growth of coarse facial and body hair, obesity, oiliness of the skin, seborrhea, and cystic acne.

Conditions

  • PCOS

Interventions

DIETARY_SUPPLEMENT

Furocyst

Furocyst caps BD

Sponsors & Collaborators

  • Chemical Resources

    lead INDUSTRY

Principal Investigators

  • Dr. Pushpalata Sankhwar, M.S. · Dept of Obs & Gynae,King George's Medical University, Lucknow, UP, India

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-26
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02703064 on ClinicalTrials.gov